EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich Assay

Nicholas J Ashton, Andrea L Benedet, Guglielmo Di Molfetta, Ilaria Pola, Federica Anastasi, Aida Fernández-Lebrero, Albert Puig-Pijoan, Ashvini Keshavan, Jonathan Schott, Kubra Tan, Joel Simrén, Bárbara Fernandes Gomes und 13 weitere

Alzheimer's & Dementia · 2025-05 · 21 (5)

DOI: 10.1002/alz.14621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 22.05.2025. Verfasst von Nicholas J Ashton und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal…. Hauptthemen laut MEDLINE: Biomarkers, Alzheimer Disease, Neurodegenerative Diseases, Lewy Body Disease. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, European Union's Horizon Europe research and innovation programme, Swedish State Support for Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Recent advancements in immunological methods accurately quantify biofluid biomarkers for Alzheimer's disease (AD) pathology. Despite progress, more biomarkers, ideally in blood, are needed for effective disease monitoring for AD and other neurodegenerative proteinopathies. METHODS We used the Nucleic Acid Linked Immuno‐Sandwich Assay (NULISA) central nervous system panel for biomarker quantification in plasma, serum, and cerebrospinal fluid of patients with AD, mild cognitive impairment, Lewy body dementia, progranulin ( GRN ) mutation carriers. RESULTS NULISA identified phosphorylated tau217 and neurofilament light chain as the most deregulated biomarkers in the AD continuum and GRN mutation carriers, respectively. Importantly, numerous novel proteomic changes were observed in each disease endophenotype, which included synaptic processing, inflammation, microglial reactivity, TAR DNA‐binding protein 43, and α‐synuclein pathology. DISCUSSION We underline the potential of next‐generation biomarker identification tools to detect novel proteomic features that also incorporate established biomarkers. These findings highlight the importance of continued biomarker discovery to improve treatment decisions and help us better understand the complexities of neurodegenerative disorders. Highlights The, direct, or indirect, measures in blood that complement phosphorylated tau (p‐tau)217 for other proteinopathies or disease progression are urgently needed. Significant novel proteomic changes were observed in each disease endophenotype in plasma, serum, and cerebrospinal fluid, which included proteins involved in synaptic processing, inflammation, microglial reactivity, TAR DNA‐binding protein 43, and α‐synuclein pathology. Nucleic Acid Linked Immuno‐Sandwich Assay continued to unbiasely highlight p‐tau217 and neurofilament light chain as the most significantly deregulated blood biomarkers in the Alzheimer's disease continuum and progranulin mutation carriers, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersAlzheimer DiseaseNeurodegenerative DiseasesLewy Body DiseaseHumanstau ProteinsMaleFemaleAgedNeurofilament ProteinsProgranulinsCognitive DysfunctionMiddle Aged

Stichwörter der Autor:innen

Lewy body diseaseNucleic Acid Linked Immuno‐Sandwich Assaydiscoveryfrontotemporal dementiaplasma biomarkersproteomics

Substanzen

Biomarkerstau ProteinsNeurofilament ProteinsProgranulinsneurofilament protein L

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Banner Alzheimer's Institute and University of Arizona, Phoenix, Arizona, USA.
  • Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Hospital del Mar Research Institute, Barcelona, Spain.
  • Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Servei de Neurologia, Hospital del Mar, Barcelona, Spain.

Förderung

  • Swedish Research Council
  • European Union's Horizon Europe research and innovation programme
  • Swedish State Support for Clinical Research
  • Alzheimer Drug Discovery Foundation
  • AD Strategic Fund
  • European Partnership on Metrology
  • NEuroBioStand
  • Bluefield Project

Zitieren

APA

Ashton, N. J., Benedet, A. L., Molfetta, G. D., Pola, I., Anastasi, F., Fernández-Lebrero, A., Puig-Pijoan, A., Keshavan, A., Schott, J., Tan, K., Simrén, J., Gomes, B. F., Montoliu-Gaya, L., Isaacson, R., Bongianni, M., Tolassi, C., Cantoni, V., Alberici, A., Padovani, A., …, & Zetterberg, H. (2025). Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich Assay. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.14621

Vancouver

Ashton NJ, Benedet AL, Molfetta GD, Pola I, Anastasi F, Fernández-Lebrero A, et al. Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich Assay. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.14621

BibTeX
@article{Ashton2025,
  author = {Ashton, Nicholas J and Benedet, Andrea L and Molfetta, Guglielmo Di and Pola, Ilaria and Anastasi, Federica and Fernández-Lebrero, Aida and Puig-Pijoan, Albert and Keshavan, Ashvini and Schott, Jonathan and Tan, Kubra and Simrén, Joel and Gomes, Bárbara Fernandes and Montoliu-Gaya, Laia and Isaacson, Richard and Bongianni, Matilde and Tolassi, Chiara and Cantoni, Valentina and Alberici, Antonella and Padovani, Alessandro and Zanusso, Gianluigi and Pilotto, Andrea and Borroni, Barbara and Suárez-Calvet, Marc and Blennow, Kaj and Zetterberg, Henrik},
  title = {Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich Assay},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {5},
  doi = {10.1002/alz.14621}
}
Kostenlos starten →